ロード中...
Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
Maraviroc is the first and, so far, the only licensed representative of the class of chemokine receptor type 5 (CCR5) inhibitors used for the treatment of human immunodeficiency virus (HIV) infection. Its safety and efficacy were demonstrated in several clinical trials, and its use was approved in 2...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3218686/ https://ncbi.nlm.nih.gov/pubmed/22096393 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/HIV.S4787 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|